TICKERNERD
Menu
BFRIBFRIHealthcare · Drug Manufacturers - Specialty & Generic

BFRI Stock Forecast: Biofrontera, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$1.36
−12.26% on the day

The 2 Wall Street analysts covering Biofrontera, Inc. hold a median 12-month price target of $6 — +341.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$23.0M
Ticker Nerd rank
67 / 100
Median analyst target
$6.00
Analysts covering
2
Revenue$12.0M+32.9% y/y
Operating income−$524K
Net income−$604K
Free cash flow−$1.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.5%
1M
+4.6%
YTD
+138.6%
1Y
+61.7%
From 52W high
−15.5%
From 52W low
+138.6%
$0.57
$1.61
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BFRI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Biofrontera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
92
Size
87
Value
82
Quality
81
Momentum
75
Volatility
44
Revisions
35
Accruals
24
Issuance
7

Growth (92): Sales and profits are climbing, and climbing faster than before.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BFRI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BFRI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26BFRIHigh $9.00Median $6.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $3.00Median $6.00High $9.00

The green dot is the last close — the median target sits +341.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 May 2026BenchmarkDowngradeSpeculative Buy$3.00
19 May 2025BenchmarkMaintainsBuy—
15 Nov 2024BenchmarkReiteratesBuy—
16 Aug 2024BenchmarkReiteratesBuy—
31 Aug 2023BenchmarkReiteratesBuy—
5 July 2023BenchmarkMaintainsBuy$140 → $18
15 May 2023BenchmarkReiteratesBuy$7.00
9 Mar 2023BenchmarkReiteratesBuy$7.00
31 Jan 2023BenchmarkReiteratesBuy$11 → $7.00
15 Dec 2021BenchmarkInitiatesBuy$11
24 Nov 2021Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BFRI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BFRI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Biofrontera, Inc. returned +61.7% against +17.5% for the S&P 500, dividends included.

BFRI vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180200Oct 25Jan 26Apr 26Jul 26BFRIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BFRI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Biofrontera, Inc. (BFRI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.9×

Cheaper than 71% of US stocks

Price / sales
0.5×

Cheaper than 82% of US stocks

Price / book
3.7×

Cheaper than 27% of US stocks

EV / EBITDA
−4.3×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
32.9%

Higher than 79% of US stocks

Earnings growth (YoY)
—
Gross margin
79.9%

Higher than 91% of US stocks

Operating margin
−4.4%

Higher than 28% of US stocks

Net margin
−13.8%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−988.4%

Higher than 2% of US stocks

Return on assets
−17.4%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Biofrontera, Inc. (BFRI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Biofrontera, Inc. has a market value of $23.0M and an enterprise value of $25.9M.

  • Revenue in the twelve months to 30 June 2026: $46.2M. The latest quarter grew 32.9% year on year.

  • Net income over the same four quarters: −$6.4M, a −13.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.60.

  • Free cash flow in the twelve months to 30 June 2026: −$7.9M.

  • Shares outstanding: 14.2M.

  • Trailing P/E: 0.9×; forward P/E: 3.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Biofrontera, Inc. employs 84 people — $550K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

BFRI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
BFRIBiofrontera, Inc.$23.0M
67
UPCUniverse Pharmaceuticals, Inc.$21.9M
34
AYTUAytu Biopharma, Inc.$21.4M
65
TXMDTherapeuticsMD, Inc.$25.0M
80
OPTHOptimi Health Corp.$25.9M
10
RMTIRockwell Medical, Inc.$31.4M
47
CPHIChina Pharma Holdings, Inc.$32.7M
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Biofrontera, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BFRI news & analysis

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

GlobeNewsWire · 14 Sept 2026positive

Biofrontera announced FDA approval of Ameluz® red light photodynamic therapy (used with the RhodoLED lamp) for the treatment of superficial basal cell carcinoma. This makes it the first and only photodynamic therapy approved in the United States to treat a skin cancer.

Why it matters — This FDA approval adds a new growth opportunity for Biofrontera's photodynamic therapy platform by expanding into the treatment of skin cancer.

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Seeking Alpha published the transcript of Biofrontera Inc.'s Q2 2026 earnings call. The item indicates the earnings call transcript is now available but provides no specific financial details or commentary.

Why it matters — A BFRI watcher would care because the earnings call transcript is the primary source for management's discussion of the company's second-quarter performance and outlook.

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 13 Aug 2026positive

Biofrontera Inc. reported a second-quarter loss of $0.05 per share, which was narrower than the Zacks Consensus Estimate of a $0.17 loss and an improvement from the $0.57 per share loss reported a year ago. The company beat revenue estimates for the quarter.

Why it matters — The narrower-than-expected loss and revenue beat signal improving financial performance relative to analyst expectations, which BFRI watchers would find relevant.

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

GlobeNewsWire · 13 Aug 2026positive

Biofrontera Inc. reported its financial results for the second quarter ended June 30, 2026, highlighting 33% revenue growth as a key driver of strong performance.

Why it matters — The 33% revenue growth signals accelerating commercial traction for Biofrontera's dermatology PDT business, a key metric for investors tracking the company's financial trajectory.

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

GlobeNewsWire · 5 Aug 2026neutral

Biofrontera Inc. (NASDAQ: BFRI) announced it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. The announcement was made via GlobeNewsWire on August 5, 2026.

Why it matters — BFRI watchers can expect the company's second-quarter 2026 results to be released on August 13, which sets the timeline for its next financial disclosure.

FAQ

Frequently asked questions about BFRI stock

What is the BFRI stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Biofrontera, Inc. have a median 12-month price target of $6, with estimates ranging from $3 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BFRI stock a buy right now?

Of the 2 analysts covering Biofrontera, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Biofrontera, Inc. 67 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BFRI?

As at 12 Sept 2026, Biofrontera, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).

Will BFRI stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +341.2% from the last close, and Ticker Nerd's factor model ranks Biofrontera, Inc. 67 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BFRI stock forecast for 2030?

No analyst covering Biofrontera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BFRI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $9 over the next 12 months.

How has BFRI stock performed over the past year?

Biofrontera, Inc. returned +61.7% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biofrontera, Inc. do?

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology products with an emphasis on photodynamic therapy.

What is the latest news on BFRI?

The most recent item we track (GlobeNewsWire, 14 Sept 2026): "Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma". Biofrontera announced FDA approval of Ameluz® red light photodynamic therapy (used with the RhodoLED lamp) for the treatment of superficial basal cell carcinoma. This makes it the first and only photodynamic therapy approved in the United States to treat a skin cancer.

Company

About Biofrontera, Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology products with an emphasis on photodynamic therapy. Its commercial portfolio centers on Ameluz, a prescription topical gel used together with BF-RhodoLED and RhodoLED lamp systems for the treatment of actinic keratoses, a common precancerous skin condition. The company also markets Xepi, a topical antibiotic for impetigo, expanding its presence in prescription skin care. Biofrontera works directly with dermatology practices and specialist groups, supporting clinical use through products designed for office-based treatment settings. Headquartered in Woburn, Massachusetts, Biofrontera plays a niche role in the dermatology market by combining drug and device-based therapies for targeted skin treatment.

CEO Dr. Hermann Luebbert Ph.D. · 84 employees · United States · https://www.biofrontera-us.com